Jason P. Hunt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason P. Hunt has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Albert Candia
19IGM Biosciences, Mountain View, California
10 shared publications - Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
10 shared publications - Asim Amin
Department of Solid Tumor and Investigational Therapeutics, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina
10 shared publications - Christopher D. Lao
Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
10 shared publications - Christopher Hoimes
Department of Medicine Duke Cancer Institute Durham North Carolina USA
10 shared publications - Cristiana Guiducci
Nurix Therapeutics, Inc., 1600 Sierra Point Parkway, Brisbane, CA 94005, USA
10 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9)
Type 2 Diabetes Risk Among Older Asian, Native Hawaiian and Pacific Islander Patients With Head and Neck Cancer in the United States
Diabetes is one of the most prevalent comorbidities among patients with head and neck cancer (HNC), and its burden is disproportionately higher in Asian American, Native Hawaiian, and Pacific Islander (ANHPI) populations. However, the incidence and risk factors for diabetes among ANHPI HNC patients remain unknown. The aim of our study was to examine the incidence and risk factors of developing Type 2 diabetes among older (≥ 66 years of age) ANHPI HNC patients in the United States, as well as differences across ANHPI subgroups. Using the SEER‐Medicare linked database, we identified Non‐Hispanic White (NHW) and ANHPI patients diagnosed with HNC from 2000 to 2019. Fine‐Gray subdistribution hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for diabetes among ANHPI subgroups compared to three reference groups: NHW, East Asian, or Chinese HNC patients. The study included 2862 older NHW, 423 East Asian, 211 Southeast Asian, 139 South Asian, and 68 NHPI HNC survivors. South Asian HNC survivors had the highest incidence of Type 2 diabetes (19.4%) compared to other ANHPI subgroups (7%–14%) and non‐Hispanic White (NHW) HNC survivors (7.5%) > 1 year after cancer diagnosis. East Asian (HR: 2.04; 95% CI: 1.36, 3.06; incidence: 14.0%) and South Asian (HR: 3.34; 95% CI: 1.86, 6.00) HNC survivors had higher diabetes risks compared to NHW HNC survivors > 1 year after cancer diagnosis, notably among Chinese and Asian Indian/Pakistani HNC survivors. Our results showed a 2‐ to 3‐fold difference in risk of Type 2 diabetes for ANHPI HNC survivors compared to NHW HNC survivors. There was a high incidence of diabetes, especially in the South and East Asian HNC patients, highlighting the need for prevention in these groups. Small sample sizes among ANHPI subgroups with fewer than 100 HNC patients (Korean, Vietnamese, NHPI) warrant cautious interpretation of these findings.
- 28 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9)
Open AccessType 2 Diabetes Risk Among Older Asian, Native Hawaiian and Pacific Islander Patients With Head and Neck Cancer in the United States
Diabetes is one of the most prevalent comorbidities among patients with head and neck cancer (HNC), and its burden is disproportionately higher in Asian American, Native Hawaiian, and Pacific Islander (ANHPI) populations. However, the incidence and risk factors for diabetes among ANHPI HNC patients remain unknown. The aim of our study was to examine the incidence and risk factors of developing Type 2 diabetes among older (≥ 66 years of age) ANHPI HNC patients in the United States, as well as differences across ANHPI subgroups. Using the SEER‐Medicare linked database, we identified Non‐Hispanic White (NHW) and ANHPI patients diagnosed with HNC from 2000 to 2019. Fine‐Gray subdistribution hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for diabetes among ANHPI subgroups compared to three reference groups: NHW, East Asian, or Chinese HNC patients. The study included 2862 older NHW, 423 East Asian, 211 Southeast Asian, 139 South Asian, and 68 NHPI HNC survivors. South Asian HNC survivors had the highest incidence of Type 2 diabetes (19.4%) compared to other ANHPI subgroups (7%–14%) and non‐Hispanic White (NHW) HNC survivors (7.5%) > 1 year after cancer diagnosis. East Asian (HR: 2.04; 95% CI: 1.36, 3.06; incidence: 14.0%) and South Asian (HR: 3.34; 95% CI: 1.86, 6.00) HNC survivors had higher diabetes risks compared to NHW HNC survivors > 1 year after cancer diagnosis, notably among Chinese and Asian Indian/Pakistani HNC survivors. Our results showed a 2‐ to 3‐fold difference in risk of Type 2 diabetes for ANHPI HNC survivors compared to NHW HNC survivors. There was a high incidence of diabetes, especially in the South and East Asian HNC patients, highlighting the need for prevention in these groups. Small sample sizes among ANHPI subgroups with fewer than 100 HNC patients (Korean, Vietnamese, NHPI) warrant cautious interpretation of these findings.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1–positive tumors
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1–positive tumors
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expression of gene signatures representing immune cell density and upregulation of functional signatures.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expression of gene signatures representing immune cell density and upregulation of functional signatures.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S1 shows additional exclusion criteria of this study.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S1 shows additional exclusion criteria of this study.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S2 describes the representativeness of study participants.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S2 describes the representativeness of study participants.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.